Hutch News
Targeting a subset of stem cells shows lasting, therapeutically relevant gene editing in blood cells
A new Science Translational Medicine paper is first to report how editing a portion of stem cells with CRISPR/Cas9 is sufficient for long-term reactivation of therapeutic hemoglobin
Cancer cells reconnect with their inner child to evade immunotherapy
Turning on an embryonic gene may help some tumors resist immune checkpoint inhibitors
New Research Identifies Gene That Hides Cancer Cells from Immunotherapy
Findings in Developmental Cell show that expression of an early developmental gene prevents the immune system from identifying and attacking cancer cells
The New Yorker spotlights Fred Hutch’s pioneering cancer research
‘The Promise and Price of Cellular Therapies’ by Siddhartha Mukherjee traces journey from bone marrow transplantation to immunotherapy
Immunotherapy trailblazer Dr. Phil Greenberg to receive E. Donnall Thomas Lecture and Prize
American Society of Hematology honors his ‘vision, creativity and scientific rigor’ in T-cell therapy research
The latest in prostate cancer research: 7 takeaways
7 takeaways from community symposium highlighting recent advances in prevention, screening and treatment
Timmerman headed for the top, again, with friends
Hutch expedition to Kilimanjaro has already raised $1 million
$12M NIH grant to study rare, aggressive skin cancer
Fred Hutch, UW researchers hope to improve immunotherapies for people with Merkel cell carcinoma
Drs. Fred Appelbaum and Phil Greenberg elected to AACR Academy
They are among 22 scientists from around the world to join the 2019 class of Fellows
On immunotherapy trial, long-term survivors of deadly skin cancer point to a hopeful future
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma
Highlights of Fred Hutch science in 2018
A look back at notable advances in immunotherapy, precision screening and more
Fred Hutch collaborates with new Allen Institute for Immunology
Multi-collaborator initiative aims to map the immune system in health and disease
Immune booster may awaken body’s defenses against skin cancer
First-in-human pilot of experimental immunotherapy in Merkel cell carcinoma
Fred Hutch at ASH: Combo CAR T-cell therapies, long-term outcomes for CAR T patients, early findings on a CAR T for multiple myeloma, gene therapy for sickle cell, and T cells and the microbiome
The 60th American Society of Hematology Annual Meeting will take place Dec. 1–4 in San Diego
Two new grants to fuel metastatic breast cancer research
Drs. Erica Goddard and Mark Headley will use their awards to study how breast cancer cells spread to distant organs – and how to stop them.
Forbes '30 Under 30' lists Hutch immunotherapy researcher Alex Salter
Grad student on short list of young health care influencers
5 questions with a cancer immunotherapy expert
Dr. Phil Greenberg to receive high honor for his contributions to the field
Metastatic breast cancer research takes the stage
Advocates, oncologists and researchers share findings, resources and reasons for hope at third annual NW Mets Conference
Standard myeloma treatment reveals itself as an immunotherapy
Mouse study shows how transplanting patients’ own healthy blood stem cells can curb cancer, opening door to better treatments
Revealing a new way that cancer can evade immunotherapy — and, maybe, how to stop it
How a new technology solved a mystery and honors one man’s legacy
Squelching ovarian cancer: the not-so-silent killer
The search continues for new biomarkers, better outcomes and, yes, cures for this deadly disease
Want to make better T-cell therapies? First, figure out how they work.
New study maps out activities, effects of widely used components in cellular immunotherapies
Drs. Siddhartha Mukherjee and Gary Gilliland in conversation
Watch: Author and physician-scientist discusses the next chapters in cancer research — and his book ‘Emperor of all Maladies’ — with Hutch President and Director
Nanoparticles open doors to cancer-fighting CAR T cells
Tiny liposome-based drug carriers make tumors more vulnerable to targeted immunotherapy